Financings in Brief: Angeion
This article was originally published in The Gray Sheet
Angeion: Files registration statement with Securities and Exchange Commission for a direct placement, principally to selected institutional investors, of 2.5 mil. shares of common stock. Proceeds will go toward R&D, clinical trials, capital equipment, leasehold improvements and general corporate purposes, the Minneapolis-based firm says. Stock in Angeion has recently been trading in the $4-6 range. The firm is developing the Sentinel implantable cardioverter defibrillator and catheter ablation systems. The offering follows a direct placement of 4.9 mil. securities last fall ("The Gray Sheet" Oct. 10, 1994, p. 20). Raymond James & Associates is placement agent for the offering...
You may also be interested in...
Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies
Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.
FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments
Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs.
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.